Corium International (CORI) PT Lowered to $14.00 at Needham & Company LLC

Corium International (NASDAQ:CORI) had its target price dropped by analysts at Needham & Company LLC to $14.00 in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 35.79% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. HC Wainwright set a $15.00 price target on Corium International and gave the stock a “buy” rating in a research note on Friday, November 17th. Zacks Investment Research cut Corium International from a “buy” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group set a $10.00 price target on Corium International and gave the stock a “buy” rating in a research note on Sunday, October 29th. Cantor Fitzgerald restated a “buy” rating and set a $14.00 price target on shares of Corium International in a research note on Friday. Finally, ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Corium International currently has an average rating of “Buy” and an average price target of $13.00.

Shares of Corium International (NASDAQ CORI) opened at $10.31 on Tuesday. Corium International has a 52 week low of $2.67 and a 52 week high of $12.32. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $371.21, a P/E ratio of -6.17 and a beta of 1.27.

In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $11.05, for a total value of $1,657,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 868,100 shares of company stock valued at $9,538,781 in the last quarter. 45.70% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its holdings in Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 40,891 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new stake in Corium International in the second quarter valued at $411,000. Teachers Advisors LLC acquired a new stake in Corium International in the second quarter valued at $272,000. EAM Investors LLC acquired a new stake in Corium International in the second quarter valued at $563,000. Finally, New York State Common Retirement Fund acquired a new stake in Corium International in the second quarter valued at $158,000. 89.35% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Corium International (CORI) PT Lowered to $14.00 at Needham & Company LLC” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/26/corium-international-cori-pt-lowered-to-14-00-at-needham-company-llc.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit